Frank Lee Sells 24,456 Shares of Bausch Health Cos (NYSE:BHC) Stock

Bausch Health Cos Inc. (NYSE:BHC) Director Frank Lee sold 24,456 shares of Bausch Health Cos stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the completion of the sale, the director directly owned 49,339 shares of the company’s stock, valued at $267,910.77. This trade represents a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bausch Health Cos Stock Down 0.6%

NYSE BHC opened at $5.47 on Friday. The stock has a fifty day moving average of $5.42 and a 200-day moving average of $6.12. The stock has a market capitalization of $2.04 billion, a P/E ratio of -1.69 and a beta of 0.42. Bausch Health Cos Inc. has a 52 week low of $4.41 and a 52 week high of $8.69. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32.

Bausch Health Cos (NYSE:BHC) last released its earnings results on Wednesday, April 29th. The company reported $0.78 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.03). The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.37 billion. Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. On average, equities research analysts forecast that Bausch Health Cos Inc. will post 4.08 EPS for the current year.

Key Bausch Health Cos News

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Zacks Research slightly raised its FY2026 EPS estimate to $3.93 from $3.92, suggesting marginally better near-term profitability expectations for Bausch Health (BHC).
• Positive Sentiment: At the company’s 2026 Annual Meeting, shareholders elected all 10 director nominees and added Eiry W. Roberts, M.D. to the board, which could support governance and strategic execution. Bausch Health Announces 2026 Annual Meeting of Shareholder Results
• Neutral Sentiment: The company also presented at the RBC Capital Markets Global Healthcare Conference, keeping attention on its strategy, operating outlook, and debt profile. Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Director Frank Lee sold 24,456 shares in a pre-arranged Rule 10b5-1 transaction, which is routine but can still weigh on sentiment. SEC Form 4 filing
• Negative Sentiment: Zacks Research cut multiple forward EPS estimates for Bausch Health (BHC), including Q2 2027, Q3 2027, Q4 2027, FY2027, Q1 2028, and FY2028, signaling softer longer-term earnings expectations.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BHC shares. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th. Barclays lowered their target price on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 25th. Royal Bank Of Canada reduced their price target on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research report on Monday, April 27th. Weiss Ratings lowered Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Finally, Wall Street Zen lowered Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Bausch Health Cos presently has a consensus rating of “Reduce” and an average price target of $8.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BHC. Caption Management LLC boosted its position in shares of Bausch Health Cos by 101.1% in the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock worth $31,000 after purchasing an additional 405,789 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Bausch Health Cos by 12,589.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after purchasing an additional 4,910 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Bausch Health Cos by 6,661.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after purchasing an additional 5,329 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after purchasing an additional 3,106 shares during the last quarter. Finally, Camelot Portfolios LLC bought a new position in shares of Bausch Health Cos in the 4th quarter worth $59,000. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.